<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506777</url>
  </required_header>
  <id_info>
    <org_study_id>MBC1</org_study_id>
    <nct_id>NCT02506777</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.</brief_title>
  <acronym>MBC1</acronym>
  <official_title>Phase II Multicenter Randomized Study to Compare Neoadjuvant FDC With Melatonin or Metformin Versus FDC Alone in The Therapy of Locally Advanced Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Petrov Research Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Petrov Research Institute of Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition melatonin and metformin to conventional chemotherapy FDC
      (Fluoruracil, Doxorubicin, cyclophosphamide) in the treatment of locally advanced breast
      cancer. Third of patients will receive FDCх6 cycles, other third will receive combination of
      melatonin and FDCх6 cycles and other patients will receive combination of metformin and FDCх6
      cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of locally advanced breast cancer is a complicated issue. For neoadjuvant
      treatment is often needed to downstage locally advanced BC tumors prior to surgery, however
      many patients do not achieved objective response during treatment. The ability of melatonin
      and metformin to decrease side effects of chemotherapy had been investigated, moreover
      several studies confirm, that this drugs in combination with conventional treatment may
      increase objective response. But, this data is still controversial. We hypothesized that
      combinations of melatonin and conventional chemotherapy regimen such as FDC could be more
      effective than FDC alone in terms of response rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months after FPFV</time_frame>
    <description>Response will evaluate by RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathomorphological response</measure>
    <time_frame>6 months after FPFV</time_frame>
    <description>Pathomorphological response will assess after surgery by Miller and Payne Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events incidence</measure>
    <time_frame>Until 30 days after last patient treatment visit</time_frame>
    <description>Incidence of AE classified using NCI Common Terminology Criteria for AE v4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>FDC x 6 cycles with metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with metformin 850 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC x 6 cycles with melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days with melatonin 3 mg before sleep daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDC x 6 cycles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>32 patients will receive 5 - Fluoruracil 500 mg/m^2, doxorubicin 50 mg/m^2, cyclophosphamide 500 mg/m^2 once every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <arm_group_label>FDC x 6 cycles with metformin</arm_group_label>
    <other_name>siofor 850</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoruracil</intervention_name>
    <arm_group_label>FDC x 6 cycles with metformin</arm_group_label>
    <arm_group_label>FDC x 6 cycles with melatonin</arm_group_label>
    <arm_group_label>FDC x 6 cycles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <arm_group_label>FDC x 6 cycles with metformin</arm_group_label>
    <arm_group_label>FDC x 6 cycles with melatonin</arm_group_label>
    <arm_group_label>FDC x 6 cycles</arm_group_label>
    <other_name>Adriablastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>FDC x 6 cycles with metformin</arm_group_label>
    <arm_group_label>FDC x 6 cycles with melatonin</arm_group_label>
    <arm_group_label>FDC x 6 cycles</arm_group_label>
    <other_name>endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <arm_group_label>FDC x 6 cycles with melatonin</arm_group_label>
    <other_name>melaxen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18. Obtained Inform Consent Morphologically confirmed breast cancer stage IIB,
             IIIA,IIIB,IIIC. ( triple negative, luminal B) Eastern Collaborative Oncology Group
             Performance Status Scale 0 - 2. Expected survival &gt;6 month Adequate liver and bone
             marrow function

        Exclusion Criteria:

          -  Systemic treatment for breast cancer IV stage disease Evidence of liver and bone
             marrow clinically meaningful disfunction Severe uncontrolled concomitant conditions
             and diseases Pregnancy or lactation Second malignancy Diabetes mellitus requiring drug
             therapy Any condition preventing study participation by investigator opinion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir F Semiglazov, MD, PhD, DSc, Professor</last_name>
    <role>Study Director</role>
    <affiliation>N.N. Petrov Research Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Y Semiglazova</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Petrov Research Institute of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
    <phone>+79219468072</phone>
    <email>tsemiglazova@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department</name>
      <address>
        <city>Saint - Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
      <phone>+79219468072</phone>
      <email>tsemiglazova@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Michael A Osipov, MD</last_name>
      <phone>+79052075653</phone>
      <email>Ocipovmixail@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petr V Krivorotko, MD, PhD, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melatonin, metformin, chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

